ZIM Laboratories Limited (NSE:ZIMLAB)
125.50
-2.52 (-1.97%)
Sep 4, 2026, 3:29 PM IST
ZIM Laboratories Revenue
ZIM Laboratories had revenue of 941.79M INR in the quarter ending June 30, 2026, with 31.25% growth. This brings the company's revenue in the last twelve months to 3.97B, up 7.52% year-over-year. In the fiscal year ending March 31, 2026, ZIM Laboratories had annual revenue of 3.74B, down -1.22%.
Revenue (ttm)
3.97B
Revenue Growth
+7.52%
P/S Ratio
1.69
Revenue / Employee
6.28M
Employees
632
Market Cap
6.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.74B | -46.31M | -1.22% |
| Mar 31, 2025 | 3.79B | 115.14M | 3.13% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Windlas Biotech | 9.42B |
| Sigachi Industries | 4.76B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.06B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |
| Sakar Healthcare | 2.72B |
| Anlon Healthcare | 2.26B |
ZIM Laboratories News
- 9 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 1 year ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 1 year ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn